Strategic Speculation: $300M Biotech with a $2 Billion Opportunity
Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) was left for dead earlier in 2024 after formally withdrawing from ...
Read moreDetailsAmylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) was left for dead earlier in 2024 after formally withdrawing from ...
Read moreDetailsStocks were indicated to open lower again on Wednesday with major equity indexes indicated down 0.3% ...
Read moreDetailsAmerican Society of Civil Engineers 2021 Infrastructure Report Card Many things are very different in the ...
Read moreDetailsStocks were down across the board on Tuesday after Monday's sell-off, but only by about 0.4% ...
Read moreDetailsStocks were indicated to open marginally lower on Monday after the Dow and S&P 500 have ...
Read moreDetailsNetflix Inc. (NASDAQ: NFLX) is proving the point that perhaps investors should pay attention when price ...
Read moreDetailsStocks had seen gains on Wednesday and were indicated higher on Thursday after TSM saved the ...
Read moreDetailsStocks took a breather on Tuesday and were then mixed on Wednesday after the semiconductor sector ...
Read moreDetailsStocks have still managed to keep challenging new highs in the Dow and S&P 500 heading ...
Read moreDetailsStocks were mixed on Monday. With some government offices and many schools closed for Columbus Day, ...
Read moreDetails
Oggonomics delivers daily stock analysis, Wall Street analyst coverage, and no-nonsense market commentary for investors who think for themselves.
Learn more

Subscribe to our weekly newsletter below and keep up with Oggonomics articles.